Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 13 for

Edit search filters
  1. Immunological Consequences of COVID-19 Vaccination in Patients with Rheumatic Diseases

    Rochester, MN

  2. Daratumumab to Treat Active Lupus Nephritis

    Rochester, MN

  3. A Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension

    Jacksonville, FL

  4. A Study to Characterize Functional Biomarkers of Systemic Lupus Erythematosus (SLE)

    Scottsdale/Phoenix, AZ

  5. Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus

    Rochester, MN

  6. A Study to Assess Omega-3 Replacement With Krill Oil in Disease Management of System Lupus Erythematosus (SLE)

    Rochester, MN

  7. Aurinia Renal Response in Active Lupus With Voclosporin

    Rochester, MN

  8. Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Patients Who Participated in ADDRESS II)

    Rochester, MN

  9. A Study of the Safety and Tolerability of JNJ-55920839, Either as a Single Ascending Dose in Healthy Individuals or as Multiple Doses for Patients who have Mild to Moderate Systemic Lupus Erythematosus

    Rochester, MN

  10. Exploring the Role of B-cell Activating Factor Receptor (BAFFR)-based Chimeric Antigen Receptor T-cell (CAR T) in BAFFR-expressing B-cell Hematologic Malignancies and Autoimmune Rheumatologic Disorders

    Jacksonville, FL

.

Mayo Clinic Footer